Skip to main content
VRDN
NASDAQ Life Sciences

Fairmount Healthcare Fund II L.P. Buys $20M in Viridian Therapeutics Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$18.25
Mkt Cap
$1.756B
52W Low
$12.07
52W High
$34.29
52W Position info
51% above low
Off High info
47% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

VRDN sits 51% above its 52-week low of $12.07.

Summary

Fairmount Healthcare Fund II L.P., a 10% owner and director-affiliated entity, made a $20 million open market purchase of Viridian Therapeutics common stock, significantly increasing its stake.


Key Events · Ownership and Investor Activity · VRDN

  • Significant Insider Purchase

    Fairmount Healthcare Fund II L.P. acquired 1,176,470 shares of common stock for $19,999,990 at a price of $17.00 per share on May 11, 2026.

  • Increased Institutional Stake

    This purchase by a 10% owner and director-affiliated entity represents a substantial increase in its holdings, demonstrating strong conviction in the company's prospects.

  • Post-Offering Investment

    The transaction occurred after recent public offerings and positive clinical trial results, but also following a stock decline due to competitor news, indicating a strategic investment at this juncture.


Analysis · VRDN · Life Sciences

This substantial open market purchase by Fairmount Healthcare Fund II L.P., a 10% owner and entity with board representation, signals strong conviction in Viridian Therapeutics. The $20 million investment, representing over 1% of the company's market capitalization, occurred shortly after the company announced positive Phase 3 data for elegrobart and concurrent public offerings, but also after a significant stock drop due to competitor news. This purchase demonstrates a significant vote of confidence from a key institutional investor.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VRDN was trading at $18.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $12.07 to $34.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VRDN - Latest Insights

VRDN
Nov 09, 2026, 7:01 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $30.00
Real-time Price: $31.80 info
Change: +$1.80 (+6%) info
Market Cap: $3.57B info
VRDN
Nov 04, 2026, 7:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.75
Real-time Price: $31.80 info
Change: +$4.05 (+15%) info
Market Cap: $3.57B info
VRDN
Nov 04, 2026, 7:01 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $27.09
Real-time Price: $31.80 info
Change: +$4.71 (+17%) info
Market Cap: $3.57B info
VRDN
Aug 06, 2026, 7:31 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $20.87
Real-time Price: $31.80 info
Change: +$10.93 (+52%) info
Market Cap: $3.57B info
VRDN
Aug 06, 2026, 7:19 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $21.50
Real-time Price: $31.80 info
Change: +$10.30 (+48%) info
Market Cap: $3.57B info